Cannabinoids Explained: THC, CBD, CBG, CBN, and the Minor Cannabinoids

Medical Disclaimer:

Homestead Health is a licensed medical cannabis processor and does not make medical claims. The information provided is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. All persons must speak to a licensed, state-registered physician to be diagnosed and/or recommended medical cannabis for a qualifying medical condition in the state of alabama.

By Homestead Health – Alabama’s Leader in Pharmaceutical-Grade Medical Cannabis Processing

Overview

Educational resource. Last reviewed: June 2026. This article defines the cannabinoids for general education. It is not medical advice and makes no claim that any cannabinoid treatments, cures, or prevents any condition. Where the science is uncertain, this article says so.

Cannabis product labels and certificates of analysis are dense with abbreviations: THC, THCA, CBD, CBDA, CBG, CBN, CBC, THCV. For a patient trying to understand what they are looking at, this alphabet soup can be baffling. This article is a plain-language glossary and guide to the cannabinoids – what they are, where they come from in the plant, how they differ, and, crucially, what the current evidence does and does not support about them.

A guiding principle runs through this piece: the marketplace has attached confident health claims to many of these compounds, and much of the scientific evidence does not yet support that confidence. An honest guide is more useful than a hopeful one, and it also happens to be the only kind of guide appropriate for a regulated medical program that prohibits health claims.

What is a Cannabinoid?

A cannabinoid is a chemical compound that interacts with the body’s cannabinoid receptors or related targets. Cannabinoids produced by the cannabis plant are called phytocannabinoids, to distinguish them from the endocannabinoids the human body makes on its own. The cannabis plant produces a large number of these compounds—by many counts, more than 150 distinct cannabinoids—although only a handful are present in significant amounts, and even fewer have been meaningfully studied in humans [1].

Cannabinoids exist alongside two other important chemical groups in cannabis: terpenes, which are aromatic compounds, and flavonoids. Together these define a plant’s chemical profile, but the cannabinoids are the compounds most directly responsible for cannabis’s characteristic effects.

A brief word on why the cannabinoid count is so often cited as “more than 150.” That figure includes not only the neutral cannabinoids most people recognize but also their acidic precursors, their degradation products, and numerous rare variants that appear only in trace amounts or in specific plant varieties. Cannabinoids are commonly grouped into neutral, acidic, and “varinic” (propyl-chain) types, the last including compounds such as THCV and CBDV [1]. The vast majority of these compounds have never been studied in humans and exist, for now, as entries on an analytical panel rather than as characterized substances. This is a useful corrective to the impression, common in marketing, that a long cannabinoid list represents a long list of understood, beneficial ingredients.

The Acid Precursors and Decarboxylation

One concept unlocks much of the confusion on a certificate of analysis: in the living plant, cannabinoids do not exist in the “active” forms most people have heard of. They exist as acidic precursors. THC begins life as THCA (tetrahydrocannabinolic acid); CBD begins as CBDA; CBG as CBGA, and so on [2].

These acidic forms convert to their familiar neutral forms through a process called decarboxylation, which removes a carboxyl group from the molecule under the influence of heat, light, or time [2]. This is why raw cannabis is not intoxicating in the way that heated cannabis is: the THCA in fresh plant material has not yet become THC. In a manufactured, finished product such as a heated gel cube or a properly processed tincture, decarboxylation has typically already occurred, so the active cannabinoids are present in their neutral forms.

There is one more elegant detail worth knowing. All of these compounds trace back to a single starting molecule. CBGA – the acid form of CBG – is often called the “mother cannabinoid,” because plant enzymes convert it into the acid precursors of THC, CBD, and CBC [3]. As the plant matures, most of the CBGA is converted onward, which is why CBG itself is usually present only at low levels in mature plants [3]. In effect, CBG is the common ancestor from which the more famous cannabinoids descend.

THC: The Principal Psychoactive Cannabinoid

Delta-9-tetrahydrocannabinol (THC) is the compound most people associate with cannabis, and for good reason: it is the primary psychoactive constituent, responsible for the intoxication or “high” [4]. Pharmacologically, THC binds directly to the CB1 receptors concentrated in the nervous system, though—as covered in our endocannabinoid system article – it does so as a relatively low-efficacy agonist, which makes its effects less linear than one might assume [4].

Because THC is the intoxicating component, it is also the cannabinoid Alabama’s program caps by dose, with a general ceiling of 50mg of delta-9-THC per day under physician oversight [5]. On labels and lab reports, THC content is the figure that most directly determines a product’s potency and legal dosing considerations.

“Total THC” and Why it Differs From THC

Certificates of analysis often list both “THC” and “Total THC.” The difference reflects decarboxylation. Total THC is a calculated value that accounts for the THCA still present in a sample, expressing the maximum THC potentially available after full conversion. It is computed by adding the directly measured THC to the THCA content adjusted by a conversion factor of roughly 0.877 (a molecule is lost during decarboxylation). For a fully decarboxylated finished product, “THC” and “Total THC” are usually close; the distinction matters most for raw or partially processed material. Our certificate-of-analysis guide covers this calculation in more depth.

CBD: Non-intoxicating and Pharmacologically Broad

Cannabidiol (CBD) is the second most well-known cannabinoid and, unlike THC, is non-intoxicating – it does not produce a high [4]. CBD’s pharmacology is notably broad and still incompletely mapped; rather than binding tightly to CB1 the way THC does, it engages a wider and more complex set of targets. This breadth is part of why CBD has attracted so much research interest, and also part of why sweeping claims about it should be read with caution: a compound with many potential mechanisms is not the same as a compound with many proven benefits.

The Minor Cannabinoids

Beyond THC and CBD lies a long list of “minor” cannabinoids – minor not in importance but in the quantities typically present. Here the gap between marketing and evidence is widest, so precision matters.

CBG (cannabigerol)

Aside from being the “mother cannabinoid” chemically, CBG has a genuinely interesting pharmacological profile, interacting with CB1 and CB2 receptors as well as other targets such as TRP channels and alpha-2 adrenoceptors across preclinical models [6]. This multi-receptor profile distinguishes it from CBD and gives researchers several mechanisms to investigate. But the human evidence remains early. A small 2024 controlled trial reported effects on anxiety and stress ratings in a modest sample of healthy adults, which researchers themselves describe as promising proof-of-concept rather than established clinical fact [6]. The honest summary: CBG is scientifically intriguing and not clinically proven.

CBN (Cannabinol)

CBN is best understood chemically as largely an oxidation product of THC—it tends to form as THC ages and degrades [6]. In the marketplace, CBN is heavily marketed as a sleep aid, but this reputation rests on a weak evidence base. A systematic review of the human CBN literature concluded that the clinical evidence for sleep-promoting effects was insufficient, with much of the underlying research dating to the 1970s and 1980s in small samples [6]. A 2024 trial found CBN affected some sleep measures but not others [6]. The “sleepy cannabinoid” label likely owes more to degraded terpenes in aged cannabis than to CBN acting on its own [6]. CBN is a clear example of a compound whose popular reputation outruns its evidence.

CBC, THCV, and CBDV

CBC (cannabichromene) is one of the more abundant minor cannabinoids but has, as of this writing, no published human clinical trials—its profile rests on preclinical (cell and animal) research only [6]. THCV (tetrahydrocannabivarin) has a dose-dependent pharmacology, behaving as a CB1 antagonist at low doses while potentially producing THC-like effects at higher doses, so describing it as simply “non-psychoactive” is inaccurate [6]. CBDV (cannabidivarin) is a non-intoxicating relative of CBD under investigation for various uses. Across all of these, the responsible framing is the same: interesting mechanisms, limited human data.

Full-Spectrum, Broad-Spectrum, and Isolate

A final piece of vocabulary appears constantly in cannabis marketing and confuses many patients: the terms full-spectrum, broad-spectrum, and isolate. These describe how many of the plant’s compounds a product retains.

• Full-spectrum products aim to preserve the plant’s complete profile of cannabinoids and terpenes, including THC.
• Broad-spectrum products retain multiple cannabinoids and terpenes but have had one component – typically THC – substantially removed.
• Isolate products contain a single purified cannabinoid, with the other plant compounds stripped away.

Marketing often implies that full-spectrum products are inherently superior because their combined compounds are said to work together – an idea rooted in the “entourage effect” hypothesis. It is important to treat that as a hypothesis rather than an established fact. The interaction between cannabinoids and terpenes is an active and legitimate area of research, but the clinical superiority of one spectrum over another is not settled science, and a patient should not assume a premium is buying a proven benefit. Our companion article on terpenes examines the entourage concept and the state of its evidence directly. For the purposes of understanding a label, the practical point is simply definitional: these terms tell you how much of the plant’s chemistry a product retains, not how well it will work for any individual.

Reading Cannabinoids On A Label

Putting this together, here is how to interpret the cannabinoid list on a product or its certificate of analysis:

• The dominant cannabinoid (usually THC in Alabama products) drives potency and dosing.
• “Total” values account for decarboxylation and are the more meaningful potency figures for finished products.
• Minor cannabinoids listed in small amounts characterize the product’s profile but should not be read as delivering the health effects marketing sometimes implies.
• “ND” or “not detected” simply means a cannabinoid on the standard panel was not found—normal for the many cannabinoids a product does not contain.

Understanding the cannabinoids alongside the certificate of analysis gives a patient an accurate picture of a product’s chemistry, which is exactly the foundation a physician conversation should build on.

The Honest State of the Evidence

It is worth stating directly, because so much cannabis content does the opposite: for most cannabinoids beyond THC and CBD, human clinical evidence is limited, preliminary, or absent [6]. Compelling laboratory and animal findings exist, and they justify continued research, but they do not justify treating any minor cannabinoid as a proven remedy. The National Academies’ comprehensive review similarly emphasized that the strength of evidence for cannabis and cannabinoids varies widely and that conclusive findings remain limited for many endpoints [7]. A patient equipped with this perspective is better protected against both disappointment and overspending than one persuaded by confident marketing.

Key takeaways

• Cannabinoids are compounds that interact with the body’s cannabinoid receptors; the plant makes more than 150, but few are abundant or well studied [1].
• In the plant, cannabinoids exist as acidic precursors (THCA, CBDA, CBGA) that convert to active forms through decarboxylation via heat, light, or time [2].
• CBGA is the “mother cannabinoid” from which THC, CBD, and CBC precursors are derived [3].
• THC is the principal psychoactive cannabinoid; CBD is non-intoxicating with a broad, still-mapped pharmacology [4].
• Minor cannabinoids like CBG, CBN, CBC, and THCV are scientifically interesting but largely unproven in humans; popular claims (e.g., CBN for sleep) often outrun the evidence [6].

Commitment to Alabama Compliance Standards

At Homestead Health, we are committed to transparency and strict compliance with all Alabama regulations. We encourage all patients to prioritize their health and legal standing by seeking only authorized, in-person care by a physician explicitly registered and recognized on AMCC’s website as a valid certifying physician.

Homestead Health Good Manufacturing Practices (GMP)

To support Alabama medical cannabis patients, Homestead Health products undergo rigorous testing protocols (Rule 538-X-6-.04). This includes high-performance liquid chromatography (HPLC) testing for cannabinoid potency and gas chromatography-mass spectrometry (GC-MS) for contaminants. We ensure that our products are free of:

• Heavy metals (lead, arsenic, mercury).
• Microbial pathogens (mold, yeast, salmonella).
• Residual solvents (from the extraction process).

Medical and editorial note: Homestead Health is a licensed medical cannabis processor and does not make medical claims. The information provided is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. All persons must speak to a licensed, state-registered physician to be diagnosed and/or recommended medical cannabis for a qualifying medical condition in the state of alabama.

Alabama Residents Also Ask

Article References

Citations Used For This Article

1. Author(s). “Major and Minor Cannabinoids” (cannabis produces 150+ cannabinoids; classification). American Journal of Endocannabinoid Medicine. 2023. https://www.endocannabinoidmedicine.com/major-and-minor-cannabinoids/
2. Author(s). “Major and Minor Cannabinoids” (acidic precursors and decarboxylation). 2023. https://www.endocannabinoidmedicine.com/major-and-minor-cannabinoids/
3. Author(s). “Minor Cannabinoids: Biosynthesis, Molecular Pharmacology and Potential Therapeutic Uses.” Frontiers in Pharmacology. 2021. https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.777804/full
4. Lucas CJ, Galettis P, Schneider J. “The pharmacokinetics and the pharmacodynamics of cannabinoids.” British Journal of Clinical Pharmacology. 2018. https://pmc.ncbi.nlm.nih.gov/articles/PMC6177698/
5. Alabama Board of Medical Examiners. “Medical Cannabis” (maximum daily dosage; 50 mg delta-9-THC ceiling). https://www.albme.gov/licensing/md-do/registrations/medical-cannabis/
6. The Cannigma. “Minor Cannabinoids Explained: CBG, CBN, THCV, CBC, and CBDV” (evidence-honest review of minor cannabinoids). April 2026. https://cannigma.com/research/minor-cannabinoids-cbg-cbn-thcv-cbc-cbdv-explained/
7. National Academies of Sciences, Engineering, and Medicine. The Health Effects of Cannabis and Cannabinoids. Washington, DC: The National Academies Press; 2017. doi:10.17226/24625. https://nap.nationalacademies.org/catalog/24625/

Additional Reading

• How Alabama Regulates Medical Cannabis: The Compassion Act and the AMCC
• The Therapeutic Potential of Terpenes and Flavonoids
• Full-Spectrum vs. Single-Molecule: The Entourage Effect in Clinical Practice
• Medical Cannabis Terpenes: A Guide to Alabama’s Clinical Care
• Understanding Chronic Pain & Alabama’s Medical Cannabis Program